Literature DB >> 3083117

The effects of external beam radiotherapy on endocrine function in patients with carcinoma of the prostate.

P W Grigsby, C A Perez.   

Abstract

Serum levels of testosterone, dihydrotestosterone, and follicle-stimulating and luteinizing hormones were determined prospectively in 59 patients with carcinoma of the prostate treated curatively with external beam radiotherapy. Hormone levels were determined before the initiation of therapy and up to 2 years following completion of therapy. Testosterone levels remained unchanged but dihydrotestosterone levels decreased slightly. Follicle-stimulating and luteinizing hormone levels increased significantly during therapy and remained elevated for up to 2 years after therapy. These findings are consistent with low dose irradiation of the testis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3083117     DOI: 10.1016/s0022-5347(17)45831-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  Advanced prostate cancer: an update.

Authors:  A Ziada; E D Crawford; F H Schröeder; M E Gleave; P D Miller; M B Garnick
Journal:  Rev Urol       Date:  2000

Review 2.  Organ-sparing approaches for testicular masses.

Authors:  Alvaro Zuniga; Nathan Lawrentschuk; Michael A S Jewett
Journal:  Nat Rev Urol       Date:  2010-08       Impact factor: 14.432

3.  Kinetics of testosterone recovery in clinically localized prostate cancer patients treated with radical prostatectomy and subsequent short-term adjuvant androgen deprivation therapy.

Authors:  Bo Dai; Yuan-Yuan Qu; Yun-Yi Kong; Ding-Wei Ye; Xu-Dong Yao; Shi-Lin Zhang; Hai-Liang Zhang; Wei-Yi Yang
Journal:  Asian J Androl       Date:  2013-05-27       Impact factor: 3.285

Review 4.  Cancer-associated bone disease.

Authors:  R Rizzoli; J-J Body; M-L Brandi; J Cannata-Andia; D Chappard; A El Maghraoui; C C Glüer; D Kendler; N Napoli; A Papaioannou; D D Pierroz; M Rahme; C H Van Poznak; T J de Villiers; G El Hajj Fuleihan
Journal:  Osteoporos Int       Date:  2013-10-22       Impact factor: 4.507

Review 5.  Skeletal sequelae of cancer and cancer treatment.

Authors:  Charles J Stava; Camilo Jimenez; Mimi I Hu; Rena Vassilopoulou-Sellin
Journal:  J Cancer Surviv       Date:  2009-05-02       Impact factor: 4.442

6.  Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppression.

Authors:  Whoon Jong Kil; Romaine C Nichols; Bradford S Hoppe; Christopher G Morris; Robert B Marcus; William Mendenhall; Nancy P Mendenhall; Zuofeng Li; Joseph A Costa; Christopher R Williams; Randal H Henderson
Journal:  Acta Oncol       Date:  2013-04       Impact factor: 4.089

7.  Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408.

Authors:  R Charles Nichols; Chen Hu; Jean-Paul Bahary; Kenneth L Zeitzer; Luis Souhami; Mark H Leibenhaut; Marvin Rotman; Elizabeth M Gore; Alexander G Balogh; David McGowan; Jeff Michalski; Adam Raben; Shari Rudoler; Christopher U Jones; Howard Sandler
Journal:  Adv Radiat Oncol       Date:  2017-08-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.